Verteporfin photodynamic therapy for neovascular age-related ...
Verteporfin photodynamic therapy for neovascular age-related ... Verteporfin photodynamic therapy for neovascular age-related ...
192 Appendix 3manufacturer’s perspective, the findings of the cohort study could at best only confirm thestatus quo; at worst, the findings could seriously damage their commercial interest.9. The size of the task was underestimated by all.10. The designation processes undertaken locally were very confused and varied greatly.Recommendations1. The NHS needs to better anticipate the requirements needed to manage the introduction ofnew treatments particularly where establishing a new treatment is likely to be complex.(Note that a recommendation has already been made through the SpecialisedCommissioning Group. This recommendation proposes that NICE, for example, involves‘on the ground’ NHS staff from both commissioning and provider organisations in discussionof the practical issues that may arise from specific pieces of guidance.)2. Establishing postlicensing studies to evaluate the introduction and use of new treatmentsshould not be considered without the explicit support of the Department of Health. Thissupport needs to be transparent and public.3. A clear set of aims and objectives must be published and made widely available beforecommencement of any cohort study to ensure that all stakeholders are fully informed andtake ownership.4. There needs to be better understanding of the role of cohort studies together with that ofregistries and databases.5. Clinicians should be better informed of the need for robust, continuing postmarketingevaluation of clinical therapies after marketing authorisation in order to ensure that resultsfrom RCTs carried out for the purposes of licensing are generalizable in everyday clinicalpractice after the RCTs have ended. The importance of continuing to acquire data on the useof treatments in everyday practice must be stressed and clinicians strongly encouraged tocollect these data particularly when introducing high cost medicines into the NHS.6. The NHS could benefit from the development of good practice guidance in relation todesignation and accreditation processes. (Some work on this has already begun in theWest Midlands.)7. The NHS could benefit from the development of good practice guidance on postlicensingcollection of data on new treatments.Overall, despite very serious obstacles, the cohort study has been established and has achieved themajority of its objectives with a large number of trusts providing good data. Wide geographicalaccess is being provided to a high standard.The review group strongly supports the development of on-going assessment of new treatmentsand for the health community and policy-makers to gain as much experience from the cohortstudy as possible. In spite of a complex set of problems that have been overcome to lesser orgreater extent, the model that has been developed by the cohort study team provides a usefulmodel for the future.Current status of the cohort studyThe study is running effectively with good rates of recruitment and data being submitted by mostdesignated providers.There has been slippage estimated at around 1 year at present. It was expected to reach a fullrecruitment rate by June 2004 but in reality only a handful of patients had been recruited by
DOI: 10.3310/hta16060Health Technology Assessment 2012; Vol. 16: No. 6193then. A year later, 1200–1500 patients had been recruited. Since the project review, a year’sextension to data collection has been provisionally funded. The study is expected to recruit untilNovember 2007.The study team continue to deal with issues around NHS implementation requiring a major timeinvestment to sort out on-going problems.Funding for treatment was not considered a major issue at the time of the review other than forthe establishment of some dedicated clinics to promote rapid referral. However, since then it hasbecome apparent that the current financial situation has resulted in clinical and nursing postsbeing frozen, waiting lists being allowed to develop and planned service developments being puton hold. In addition, the effects of national tariffs under Payment By Results are causing concernand generating uncertainties in the minds of managers in designated provider trusts. Indeed thewhole issue of funding flows is confused. It is likely that there are problems at all levels: failure ofsome commissioners to fully fund the cohort study, failure of some trusts not to forward fundsgiven for the cohort study and treatment to clinical teams and also some trusts receiving moneyfor the cohort study but not entering patients into the study.Compliance among clinicians with respect to the collection and submission of high-qualitydata continues to be an important problem. Some providers are receiving funding to providephotodynamic therapy but are not participating in the study. The Steering Group constantlymonitor this situation.Data collection is still being established at some sites.A number of centres are reporting considerable delays in getting patients to treating centres –such that a significant percentage of referrals are deemed ineligible for treatment owing to thepoor level of visual acuity in the eye being assessed, suggesting that earlier referral would haveresulted in the patient receiving treatment.Alternative treatments with antiangiogenic drugs with equivalent efficacy to VPDT and,potentially, wider application are due to be licensed for use in this condition during 2006–7. Itcan be anticipated that the implementation of these new treatments will present a major problemfor the NHS as well as a threat to the cohort study.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Reeves et al. under the terms of a commissioning contract issued by theSecretary of State for Health.
- Page 156 and 157: 142 Appendix 1something to do with
- Page 158 and 159: 144 Appendix 1College of Ophthalmol
- Page 160 and 161: 146 Appendix 1Appendix 5:Protocol f
- Page 162 and 163: 148 Appendix 16.2 Subjective Refrac
- Page 164 and 165: 150 Appendix 1• The patient shoul
- Page 166 and 167: 152 Appendix 1Appendix 6:Protocol f
- Page 168 and 169: 154 Appendix 18. It is customary to
- Page 170 and 171: 156 Appendix 1Early or Transit Phas
- Page 172 and 173: 158 Appendix 1
- Page 174 and 175: 160 Appendix 1---------------------
- Page 176 and 177: 162 Appendix 1---------------------
- Page 178 and 179: 164 Appendix 1---------------------
- Page 180 and 181: 166 Appendix 1Appendix 9:Site imple
- Page 182 and 183: 168 Appendix 1Option 2 - units inte
- Page 184 and 185: 170 Appendix 1Dos and Don’tsDosDo
- Page 186 and 187: 172 Appendix 1Resource use question
- Page 188 and 189: 174 Appendix 1Appendix 11: Recommen
- Page 190 and 191: 176 Appendix 1ADVERSE REACTION AND
- Page 192 and 193: 178 Appendix 1acute Trust; note tha
- Page 194 and 195: 180 Appendix 1Ophthalmologistrespon
- Page 197 and 198: DOI: 10.3310/hta16060Health Technol
- Page 199 and 200: DOI: 10.3310/hta16060Health Technol
- Page 201 and 202: DOI: 10.3310/hta16060Health Technol
- Page 203: DOI: 10.3310/hta16060Health Technol
- Page 209 and 210: DOI: 10.3310/hta16060Health Technol
- Page 211 and 212: DOI: 10.3310/hta16060Health Technol
- Page 213 and 214: DOI: 10.3310/hta16060Health Technol
- Page 216: FeedbackThe HTA programme and the a
DOI: 10.3310/hta16060Health Technology Assessment 2012; Vol. 16: No. 6193then. A year later, 1200–1500 patients had been recruited. Since the project review, a year’sextension to data collection has been provisionally funded. The study is expected to recruit untilNovember 2007.The study team continue to deal with issues around NHS implementation requiring a major timeinvestment to sort out on-going problems.Funding <strong>for</strong> treatment was not considered a major issue at the time of the review other than <strong>for</strong>the establishment of some dedicated clinics to promote rapid referral. However, since then it hasbecome apparent that the current financial situation has resulted in clinical and nursing postsbeing frozen, waiting lists being allowed to develop and planned service developments being puton hold. In addition, the effects of national tariffs under Payment By Results are causing concernand generating uncertainties in the minds of man<strong>age</strong>rs in designated provider trusts. Indeed thewhole issue of funding flows is confused. It is likely that there are problems at all levels: failure ofsome commissioners to fully fund the cohort study, failure of some trusts not to <strong>for</strong>ward fundsgiven <strong>for</strong> the cohort study and treatment to clinical teams and also some trusts receiving money<strong>for</strong> the cohort study but not entering patients into the study.Compliance among clinicians with respect to the collection and submission of high-qualitydata continues to be an important problem. Some providers are receiving funding to provide<strong>photodynamic</strong> <strong>therapy</strong> but are not participating in the study. The Steering Group constantlymonitor this situation.Data collection is still being established at some sites.A number of centres are reporting considerable delays in getting patients to treating centres –such that a significant percent<strong>age</strong> of referrals are deemed ineligible <strong>for</strong> treatment owing to thepoor level of visual acuity in the eye being assessed, suggesting that earlier referral would haveresulted in the patient receiving treatment.Alternative treatments with antiangiogenic drugs with equivalent efficacy to VPDT and,potentially, wider application are due to be licensed <strong>for</strong> use in this condition during 2006–7. Itcan be anticipated that the implementation of these new treatments will present a major problem<strong>for</strong> the NHS as well as a threat to the cohort study.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Reeves et al. under the terms of a commissioning contract issued by theSecretary of State <strong>for</strong> Health.
Change language